People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Many people with depression and anxiety in the U.S. could benefit from medication but do not receive any treatment, psychiatrist Mark Olfson told Newsweek.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

In her new book, psychiatrist Joanna Moncrieff examines the popular belief that antidepressants "work." Among many other ...

Rates of post-traumatic stress disorder (PTSD) combined with anxiety disorders or diagnoses of depression increased by 177% ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...